Ontology highlight
ABSTRACT:
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: Masaaki Oyama
PROVIDER: PXD048275 | JPOST Repository | Fri Mar 08 00:00:00 GMT 2024
REPOSITORIES: jPOST
| Action | DRS | |||
|---|---|---|---|---|
| 20220712_kaito_3.raw | Raw | |||
| 20220712_kaito_4.raw | Raw | |||
| 20220721_hata_20220712_kaito_3.xlsx | Xlsx | |||
| 20220721_hata_20220712_kaito_4.xlsx | Xlsx |
Items per page: 5 1 - 4 of 4 |

Kaito Satoshi S Aoyama Kazumasa K Oshima Motohiko M Tsuchiya Akiho A Miyota Makiko M Yamashita Masayuki M Koide Shuhei S Nakajima-Takagi Yaeko Y Kozuka-Hata Hiroko H Oyama Masaaki M Yogo Takao T Yabushita Tomohiro T Ito Ryoji R Ueno Masaya M Hirao Atsushi A Tohyama Kaoru K Li Chao C Kawabata Kimihito Cojin KC Yamaguchi Kiyoshi K Furukawa Yoichi Y Kosako Hidetaka H Yoshimi Akihide A Goyama Susumu S Nannya Yasuhito Y Ogawa Seishi S Agger Karl K Helin Kristian K Yamazaki Satoshi S Koseki Haruhiko H Doki Noriko N Harada Yuka Y Harada Hironori H Nishiyama Atsuya A Nakanishi Makoto M Iwama Atsushi A
Nature communications 20240828 1
DNA hypomethylating agents (HMAs) are used for the treatment of myeloid malignancies, although their therapeutic effects have been unsatisfactory. Here we show that CRISPR-Cas9 screening reveals that knockout of topoisomerase 1-binding arginine/serine-rich protein (TOPORS), which encodes a ubiquitin/SUMO E3 ligase, augments the efficacy of HMAs on myeloid leukemic cells with little effect on normal hematopoiesis, suggesting that TOPORS is involved in resistance to HMAs. HMAs are incorporated int ...[more]